About CND Life Sciences
CND Life Sciences is a company based in Phoenix (United States) founded in 2017 by Roy Freeman, Christopher Gibbons, and Todd Dylan Levine.. CND Life Sciences has raised $37.51 million across 11 funding rounds from investors including LabCorp, NIH and HHS. CND Life Sciences offers products and services including Syn-One Test and Small-Fiber DX. CND Life Sciences operates in a competitive market with competitors including BioShai, iNeuroskill, Itr Diagnostics and Parkinsor, among others.
- Headquarter Phoenix, United States
- Founders Roy Freeman, Christopher Gibbons, Todd Dylan Levine
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$37.51 M (USD)
in 11 rounds
-
Latest Funding Round
$13.5 M (USD), Series A
May 01, 2025
-
Investors
LabCorp
& 11 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CND Life Sciences
CND Life Sciences offers a comprehensive portfolio of products and services, including Syn-One Test and Small-Fiber DX. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Skin-based test for diagnosing Parkinson's and related synucleinopathies.
Test for detecting small-fiber neuropathy in patients.
Unlock access to complete
Unlock access to complete
Funding Insights of CND Life Sciences
CND Life Sciences has successfully raised a total of $37.51M across 11 strategic funding rounds. The most recent funding activity was a Series A round of $13.5 million completed in May 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 11
- Last Round Series A — $13.5M
-
First Round
First Round
(30 Sep 2020)
- Investors Count 12
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2025 | Amount | Series A - CND Life Sciences | Valuation |
investors |
|
| Feb, 2025 | Amount | Series A - CND Life Sciences | Valuation |
investors |
|
| Mar, 2024 | Amount | Seed - CND Life Sciences | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in CND Life Sciences
CND Life Sciences has secured backing from 12 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include LabCorp, NIH and HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Early-stage companies are supported with growth capital investments.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by CND Life Sciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - CND Life Sciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cnd Life Sciences Comparisons
Competitors of CND Life Sciences
CND Life Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BioShai, iNeuroskill, Itr Diagnostics and Parkinsor, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Offers blood-based tests for early diagnosis of Parkinson's disease.
|
|
| domain | founded_year | HQ Location |
A device that monitors the progression of neurological disorders by measuring motor skill characteristics.
|
|
| domain | founded_year | HQ Location |
Provides diagnostic tests for neurological diseases.
|
|
| domain | founded_year | HQ Location |
Develops diagnostic tools for diagnosing and treating Parkinson's disease.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cnd Life Sciences
Frequently Asked Questions about CND Life Sciences
When was CND Life Sciences founded?
CND Life Sciences was founded in 2017 and raised its 1st funding round 3 years after it was founded.
Where is CND Life Sciences located?
CND Life Sciences is headquartered in Phoenix, United States. It is registered at Phoenix, Arizona, United States.
Who is the current CEO of CND Life Sciences?
Richard J Morello is the current CEO of CND Life Sciences.
Is CND Life Sciences a funded company?
CND Life Sciences is a funded company, having raised a total of $37.51M across 11 funding rounds to date. The company's 1st funding round was a Seed of $2.01M, raised on Sep 30, 2020.
What does CND Life Sciences do?
Provider of a neurological disease diagnostic tool for providers. The company has developed a diagnostic kit called Syn-One Test which assists in the diagnosis of synucleinopathy in patients. The kit is a skin biopsy tool that has the ability to detect and visualize abnormal skin cell conditions based on pathological evidence.
Who are the top competitors of CND Life Sciences?
CND Life Sciences's top competitors include BioShai, iNeuroskill and Itr Diagnostics.
What products or services does CND Life Sciences offer?
CND Life Sciences offers Syn-One Test and Small-Fiber DX.
Who are CND Life Sciences's investors?
CND Life Sciences has 12 investors. Key investors include LabCorp, NIH, HHS, Tanis Ventures, and Top Corner Capital.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.